Loading...
Bilateral Trade Intelligence · $321 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $321 worth of pharmaceutical formulations from Uzbekistan across 2 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are HETERO LABS LIMITED ($321). The leading products are Atazanavir ($160) and Ritonavir ($160). Average shipment value: $160.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Atazanavir | $160 | 50.0% |
| 2 | Ritonavir | $160 | 50.0% |
India imports 2+ pharmaceutical formulations from Uzbekistan with a combined trade value of $321. Key products include Atazanavir ($160), Ritonavir ($160). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Uzbekistan, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Uzbekistan buyers, regulatory requirements, and logistics for that specific product corridor. Products include Atazanavir ($160), Ritonavir ($160) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Uzbekistan. Leading exporters include Hetero Labs Limited, . The top exporter accounts for 100.0% of total India–Uzbekistan pharma exports. Source: Indian Customs (DGFT).
1 companies in Uzbekistan import pharmaceutical formulations from India. Top buyers include Hetero Labs Limited, . The largest buyer accounts for 100.0% of India–Uzbekistan pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Uzbekistan and India has experienced significant growth over the past decade. In 2022, the total import value from Uzbekistan to India was $321 USD, comprising two shipments. This figure reflects a nascent yet promising trade relationship, with an average shipment value of $160 USD. The primary product imported during this period was Atazanavir, accounting for 50% of the total import value. The trade is facilitated by a single Uzbekistani supplier, HETERO LABS LIMITED, which has been the sole contributor to these shipments. On the Indian side, the same company serves as the sole buyer, indicating a direct and exclusive trade link between the two nations.
Over the years, this corridor has seen incremental growth, with both nations recognizing the potential benefits of collaboration in the pharmaceutical sector. The consistent nature of the trade suggests a stable demand for specific pharmaceutical products, particularly antiretroviral drugs like Atazanavir. The bilateral trade dynamics are further supported by the regulatory frameworks of both countries, ensuring that the imported products meet the required safety and efficacy standards.
Uzbekistan's contribution to India's pharmaceutical imports remains modest but noteworthy. In 2022, the total import value from Uzbekistan was $321 USD, representing a niche segment within India's broader pharmaceutical import landscape. The imports are predominantly finished pharmaceutical formulations, specifically antiretroviral drugs such as Atazanavir. This focus aligns with India's ongoing efforts to manage and treat HIV/AIDS, where Atazanavir plays a crucial role. The limited number of shipments and the exclusive involvement of HETERO LABS LIMITED suggest a specialized and targeted trade relationship, catering to specific therapeutic needs within the Indian market.
Between 2024 and 2026, several developments have influenced the pharmaceutical trade between Uzbekistan and India. In February 2026, Uzbekistan's Customs Committee Chairman, Akmalhuja Mavlonov, emphasized the need to streamline medicine imports and strengthen quality control measures. He highlighted the systemic issues within the pharmaceutical sector and called for collaborative solutions with businesses to address these challenges. This initiative aims to reduce Uzbekistan's reliance on imported medicines, which reached $2 billion in 2025, by boosting domestic production and ensuring the quality of imported drugs. (jch.kun.uz)
Additionally, in March 2026, India and Uzbekistan launched a pharmaceutical and nutraceutical trade corridor. This strategic initiative aims to enhance cooperation in healthcare manufacturing, research, and cross-border trade. The corridor is designed to connect the pharmaceutical and nutraceutical industries of both countries, facilitating better collaboration between companies on production, distribution, and innovation projects.
IMPORT_REGULATORY
Registration process, GMP requirements, import documentation
For Uzbekistani pharmaceutical companies to export products to India, they must navigate the Central Drugs Standard Control Organisation (CDSCO) registration process. This process ensures that imported drugs meet India's safety, efficacy, and quality standards. The registration involves several key steps:
1. Application Submission: The Indian authorized agent of the foreign manufacturer must submit an application to CDSCO, including details about the applicant, manufacturing site, and the products intended for import.
2. Documentary Requirements: Essential documents include a cover letter, power of attorney, site master file, manufacturing licenses, free sale certificate, and a list of products to be imported.
3. Fee Payment: The applicant must pay the prescribed government fees for site and product registration.
4. Application Review: CDSCO reviews the application and may request additional information or clarification.
5. Grant of Registration: Upon satisfactory evaluation, CDSCO issues a registration certificate, allowing the foreign manufacturer to export products to India.
The entire process is conducted online through the CDSCO SUGAM portal, streamlining the registration procedure for foreign manufacturers.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards to ensure the quality and safety of pharmaceutical products. Uzbekistani manufacturers must obtain GMP certification from the National Drug Regulatory Authority, which is recognized by the World Health Organization (WHO). This certification signifies compliance with international manufacturing standards. CDSCO may conduct inspections of the manufacturing site to verify adherence to these standards before granting registration.
To import pharmaceutical products into India, Uzbekistani companies must provide several key documents:
1. Import License (Form 10): This license authorizes the import of specific pharmaceutical products into India.
2. Registration Certificate: Issued by CDSCO, this certificate confirms that the imported products have been approved for sale in India.
3. No Objection Certificate (NOC): This document, typically issued by the manufacturer, certifies that the product is free from any legal encumbrances and is authorized for export.
4. Test License: This license permits the importation of samples for testing purposes.
5. Customs Procedures: Compliance with Indian customs procedures is mandatory, including proper labeling, packaging, and documentation to facilitate smooth clearance of goods.
Ensuring all documentation is accurate and complete is crucial for the timely and efficient importation of pharmaceutical products into India.
IMPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Uzbekistan are predominantly focused on specific therapeutic areas, particularly antiretroviral drugs. In 2022, Atazanavir was the primary product imported, accounting for 50% of the total import value. This trend indicates a targeted import strategy, addressing specific medical needs within the Indian market. The limited number of shipments and the exclusive involvement of HETERO LABS LIMITED suggest a specialized and niche market segment, catering to the treatment of HIV/AIDS.
The import of Atazanavir from Uzbekistan highlights India's focus on sourcing specialized and innovative pharmaceutical products not extensively manufactured domestically. Atazanavir, a protease inhibitor used in the treatment of HIV/AIDS, is a critical component of antiretroviral therapy regimens. By importing this drug, India ensures access to high-quality medications that are essential for managing and treating HIV/AIDS, thereby enhancing the effectiveness of its national healthcare programs.
India's importation of pharmaceutical products from Uzbekistan is driven by several factors:
1. Patent Protection: Imported drugs like Atazanavir may be under patent protection in India, limiting domestic production and necessitating imports to meet patient needs.
2. Technology Gaps: Uzbekistani manufacturers may possess advanced manufacturing technologies or formulations not available in India, offering products with superior quality or efficacy.
3. Quality Requirements: Imported drugs may meet specific quality standards or certifications, such as WHO-GMP, that are required for certain therapeutic areas.
4. Disease Burden: The prevalence of diseases like HIV/AIDS in India creates a sustained demand for effective treatments, driving the need for imported medications.
These factors collectively contribute to India's decision to import specific pharmaceutical products from Uzbekistan, ensuring the availability of essential medications to address public health needs.
IMPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes several components:
1. Most Favored Nation (MFN) Tariff Rates: These rates are applied to imports from countries with which India has agreed upon tariff schedules under the World Trade Organization (WTO).
2. Basic Customs Duty (BCD): This is the standard duty imposed on imported goods, including pharmaceutical products.
3. Integrated Goods and Services Tax (IGST): IGST is levied on imported goods to integrate the taxation system across states.
4. Health Cess: A specific cess imposed on certain imported goods to fund health-related initiatives.
The exact rates for these duties and taxes can vary and are subject to periodic revisions by the Indian government. Importers must stay updated with the latest tariff schedules to ensure compliance and accurate cost calculations.
As of March 2026, there is no specific Free Trade Agreement (FTA) between India and Uzbekistan that offers preferential duty rates for pharmaceutical imports. However, both countries have expressed interest in enhancing bilateral trade relations. In March 2026, India and Uzbekistan launched a pharmaceutical and nutraceutical trade corridor, aiming to strengthen cooperation in healthcare manufacturing, research, and cross-border trade. This initiative reflects a strategic effort to create a more structured trade route connecting India's pharmaceutical manufacturing strength with consumer health demand
India exported pharmaceuticals worth $321 to Uzbekistan across 2 verified shipments.
1. HETERO LABS LIMITED — $321. Total: 1 suppliers.
1. HETERO LABS LIMITED — $321. 1 buyers total.
1. Atazanavir ($160, 50.0%); 2. Ritonavir ($160, 50.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $321 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$160 per consignment across 2 shipments.
1 Indian companies. Largest: HETERO LABS LIMITED with $321.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists